نتایج جستجو برای: high dose cytarabine

تعداد نتایج: 2292508  

Journal: :Blood 2011
Hugo F Fernandez Zhuoxin Sun Mark R Litzow Selina M Luger Elisabeth M Paietta Janis Racevskis Gordon Dewald Rhett P Ketterling Jacob M Rowe Hillard M Lazarus Martin S Tallman

We report the results of a prospective, randomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation approach in 657 patients 17-60 years of age. Patients in first complete remission (CR1) after cytarabine and standard- or high-dose daunorubicin induction received 2 cycles of consolidation with high-dose cytarabine followed by peripheral blood progenit...

Journal: :British journal of haematology 2005
J Palle B M Frost E Forestier G Gustafsson P Nygren M Hellebostad O G Jonsson J Kanerva K Schmiegelow R Larsson G Lönnerholm

Rearrangements in the 11q23 region, the site of the mixed lineage leukaemia (MLL) gene, are found in both childhood acute myeloid (AML) and lymphoblastic (ALL) leukaemia. We studied the in vitro drug resistance by the fluorometric microculture cytotoxicity assay (FMCA) in 132 children with AML and 178 children with ALL (aged 0-17 years). In AML, children with t(9;11) (n = 10) were significantly...

Journal: :EJHaem 2023

Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm characterized by the infiltration of blood and bone marrow immature monocytes, in which extra-hematopoietic localization uncommon. We report case 69-year-old-man with highly likely ectopic brain CMML involvement MRI. Without possibility cerebral biopsy negative infectious disease assessment, high-dose cytara...

2014
Wenjun Zhang Yi Ding Hao Wu Yuhua Chen Huina Lu Chunying Chen Jianfei Fu Weiguang Wang Aibin Liang Shanhua Zou Alberto Zaniboni.

This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission. Disease-free survival (DFS) and overall survival (OS) based on age (≥ 60, <60 years) and cytogenetics were evaluated from data be...

Journal: :The New England journal of medicine 2003
Stephen G O'Brien François Guilhot Richard A Larson Insa Gathmann Michele Baccarani Francisco Cervantes Jan J Cornelissen Thomas Fischer Andreas Hochhaus Timothy Hughes Klaus Lechner Johan L Nielsen Philippe Rousselot Josy Reiffers Giuseppe Saglio John Shepherd Bengt Simonsson Alois Gratwohl John M Goldman Hagop Kantarjian Kerry Taylor Gregor Verhoef Ann E Bolton Renaud Capdeville Brian J Druker

BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. METHODS We randomly assigned 1106 patients to ...

Journal: :Cochrane Database of Systematic Reviews 2016

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010
Andreas Josting Horst Müller Peter Borchmann Joke W Baars Bernd Metzner Hartmut Döhner Igor Aurer Lenka Smardova Thomas Fischer Dietger Niederwieser Kerstin Schäfer-Eckart Norbert Schmitz Anna Sureda Jan Glossmann Volker Diehl Daphne DeJong Martin-Leo Hansmann John Raemaekers Andreas Engert

PURPOSE High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS AND METHODS Patients with histol...

Journal: :Clinical journal of oncology nursing 2015
Stephanie Szoch Karen Snow Kaiser

Patients receiving high-dose cytarabine as part of their chemotherapy regimen have a chance of experiencing neurotoxicities. Prompt identification of signs and symptoms can greatly reduce the chance of patients sustaining permanent neurologic damage. This article describes the development and successful implementation of an evidence-based, standardized neurologic assessment and documentation to...

Journal: :BMJ case reports 2013
Nischala Ammannagari Quanhathai Kaewpoowat Supawat Ratanapo Anush Patel

To cite: Ammannagari N, Kaewpoowat Q, Ratanapo S, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2012008159 DESCRIPTION A 64-year-old gentleman was diagnosed with acute myeloid leukaemia (AML) 3 years ago and was treated with cytarabine and daunorubicin induction chemotherapy followed by three cycles of highdose cytarabine consolidation treatment. Patient ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید